Cell Biology Immune Response Research 
Drug Target Review
OCTOBER 16, 2023
They self-assemble and in doing so retain the genetics, structure and heterogeneity of cell types found in the tissue they derive from. Their close resemblance to the patient and disease state makes PDOs a valuable and scalable source of biological material to interrogate in disease research and drug discovery.
Drug Discovery World
APRIL 14, 2023
The American Association for Cancer Research (AACR) will honour the following cancer researchers, physician-scientists, advocates, and journalists during its annual meeting to be held April 14-19 at the Orange County Convention Center in Orlando, Florida. June’s award lecture will be held on Sunday April 16 at 4:30pm ET.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Discovery World
AUGUST 31, 2023
Researchers have identified stem cells in the human thymus for the first time, representing a potential new target to understand immune diseases and cancer. The thymus is a gland located in the front part of the chest, the place where thymocytes (the cells in the thymus) mature into T cells.
The Pharma Data
JANUARY 3, 2021
We are very honored to have someone of Dr. Zeldis’ caliber lead our scientific research and clinical development teams. Both Jerry and Jeff have proven and successful track records in the design and execution of early and late-stage clinical trials that have evaluated novel immune therapies. . GAITHERSBURG, Md.,
Broad Institute
OCTOBER 11, 2023
By Allessandra DiCorato October 11, 2023 In 2011, Robert Manguso was working in a cell biology lab when his mother was diagnosed with Merkel cell carcinoma, a rare and aggressive skin cancer. They are used to treat cancers including melanoma and non-small cell lung cancer, but work only for a small fraction of patients.
Drug Target Review
NOVEMBER 17, 2023
NK cells are among the front line of protection from infected and abnormal cells as part of the ‘innate immune response’. They recognise ‘cell stress molecules’ on the surface of infected, old, injured and cancerous cells without the need for complex pre-stimulation signals of the adaptive immune system (eg, T cells).
The Pharma Data
DECEMBER 31, 2020
Researchers at Stanford Medicine found that COVID-19 antibodies preferentially target different parts of the SARS-CoV-2 virus in mild COVID-19 cases than they do in severe cases. Antibody responses are not likely to be the sole determinant of someone’s outcome,” said Scott Boyd, associate professor of pathology at Stanford.
Expert insights. Personalized for you.
122 
Let's personalize your content